Literature DB >> 17694260

Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan.

Hisashi Yamanaka1, Eisuke Inoue, Gurkirpal Singh, Eiichi Tanaka, Ayako Nakajima, Atsuo Taniguchi, Masako Hara, Taisuke Tomatsu, Naoyuki Kamatani.   

Abstract

The objective of this study was to show whether the disease activity of rheumatoid arthritis (RA) patients had improved in Japan, and whether the improvement of disease activity had resulted in a better outcome of patients. In a single-institute-based prospective observational cohort of RA patients (Institute of Rheumatology, Rheumatoid Arthritis, IORRA), a total of 7512 patients were enrolled, and their information was collected biannually. A cross-sectional data set A that included all patients in each phase was analyzed. From October 2000 to April 2006, disease activity score DAS28 significantly improved from 4.15 to 3.63, and the frequency of patients in remission (DAS28 < 2.6) increased from 8.5% to 21.5%. During this period, the frequency of methotrexate users increased from 33.9% to 58.7% and the average dosage of methotrexate also increased from 5.59 mg/week to 6.94 mg/week; on the other hand, there was no increase in any adverse reaction among the methotrexate users. To investigate the relationship between longitudinal disease control and progression of disability, a longitudinal data set B that included 712 patients who completed all phases of the study from 2000 to 2006 was selected and was analyzed. The disability index JHAQ of a poorly controlled group (average DAS > 5.1) increased (+34.8%), that of a moderately controlled group (average DAS 3.2-5.1) also increased (+14.0%), but that of a well-controlled group (average DAS < 3.2) decreased (-13.0%). In conclusion, by using a prospective observational cohort IORRA in Japan, we demonstrate that RA disease activity improved from 2000 to 2006, which correlates with an increased use of methotrexate. The suppression of disease activity resulted in a better outcome for patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694260     DOI: 10.1007/s10165-007-0587-6

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  15 in total

1.  Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Authors:  Toru Yamada; Ayako Nakajima; Eisuke Inoue; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

2.  Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis.

Authors:  Ayako Nakajima; Eisuke Inoue; Yoko Shimizu; Akiko Kobayashi; Kumi Shidara; Naoki Sugimoto; Yohei Seto; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2014-07-31       Impact factor: 2.980

3.  Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore.

Authors:  Ee Tzun Koh; Justina Wei Lynn Tan; Bernard Yu-Hor Thong; Cheng Lay Teh; Tsui Yee Lian; Weng Giap Law; Arul Earnest; Kok Ooi Kong; Tang Ching Lau; Yew Kuang Cheng; Hwee Siew Howe; Wern Hui Yong; Faith Li-Ann Chia; Hiok Hee Chng; Khai Pang Leong
Journal:  Rheumatol Int       Date:  2012-12-28       Impact factor: 2.631

4.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

5.  Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.

Authors:  Kumi Shidara; Eisuke Inoue; Daisuke Hoshi; Eri Sato; Ayako Nakajima; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-11-27       Impact factor: 2.631

6.  Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture.

Authors:  K Ochi; E Inoue; T Furuya; K Ikari; Y Toyama; A Taniguchi; H Yamanaka; S Momohara
Journal:  Osteoporos Int       Date:  2014-10-08       Impact factor: 4.507

7.  Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.

Authors:  Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon
Journal:  J Rheumatol       Date:  2014-10-15       Impact factor: 4.666

Review 8.  Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.

Authors:  Gabriela Schmajuk; Daniel H Solomon; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

9.  Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis.

Authors:  Chen Yu; Shangyi Jin; Yanhong Wang; Nan Jiang; Chanyuan Wu; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-10-19       Impact factor: 2.980

Review 10.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.